GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

XBIO · Sep 30, 2025

Xenetic Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001683168-25-008259General Corporate
Operating cash generation100thOwn-history percentile · N=19
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-64.10% · OPTIONAL · VALID

Revenue growth87thOwn-history percentile · N=15
Evidence method

Yoy · gp.fundamentals.revenue

67.19% · CORE · VALID

Operating margin100thOwn-history percentile · N=19
Evidence method

Level · gp.fundamentals.operating_margin

-53.04% · CORE · VALID

R&D intensity5thOwn-history percentile · N=19
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

73.66% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=19
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1.54% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Increased
Previous
-65.07%
Current
-64.10%
Delta
0.97%
Growth Increased
Previous
-18.79%
Current
67.19%
Delta
85.98%
Profitability Increased
Previous
-122.80%
Current
-53.04%
Delta
69.76%
R And D Intensity Decreased
Previous
111.30%
Current
73.66%
Delta
-37.64%
Sbc Intensity Decreased
Previous
2.66%
Current
1.54%
Delta
-1.11%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.